3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
aldesleukin
15
pembrolizumab
11
Cyclophosphamide
9
fludarabine phosphate
7
fludarabine
6
Nivolumab
6
Interleukin-2
6
atezolizumab
5
Radiotherapy
5
Ipilimumab
4
Interferon-alpha
4
Drug Therapy
4
Blood Specimen Collection
4
Radiosurgery
3
tremelimumab
2
temsirolimus
2
durvalumab
2
cemiplimab
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Paclitaxel
2
Metformin
2
Interleukin-12 Subunit p35
2
Genistein
2
Gene Expression Profiling
2
Flow Cytometry
2
Filgrastim
2
Cetuximab
2
zanolimumab
1
vivitrol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Genetic Counseling
×
Dermatologic
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled